Several lawmakers are pushing to repeal or revisit a law critics say enables the flow of deadly and addictive opioids, hours after President Trump’s drug czar nominee withdrew his name amid the controversy.

The little-noticed legislation is reportedly undermining the Drug Enforcement Administration’s (DEA) ability to police drug distributors and was heavily influenced by industry lobbying, according to a joint Washington Post and “60 Minutes” investigation published Sunday. The report was based in part on a high-ranking whistleblower within the DEA.

The controversy comes as the nation is grappling with an opioid crisis, with the rate of overdoses from prescription drugs and heroin quadrupling since 1999. Lawmakers are taking a new look at the law following the report, with several seeking an outright repeal.

ADVERTISEMENT

“Of course it should be fixed,” Sen. John McCain John Sidney McCainMomentum growing among Republicans for Supreme Court vote before Election Day McConnell urges GOP senators to 'keep your powder dry' on Supreme Court vacancy McSally says current Senate should vote on Trump nominee MORE (R-Ariz.) said.

The Ensuring Patient Access and Effective Drug Enforcement Act passed in 2016 with little fanfare, and no objections in the House or the Senate. President Obama then signed it into law.

By raising the standard of evidence required by DEA, critics say it weakened their authority to prosecute drug distributors that were providing opioids onto the market with little oversight, according to the investigation.

Asked if the bill should be repealed or amended, Senate Majority Leader Mitch McConnell Addison (Mitch) Mitchell McConnellMomentum growing among Republicans for Supreme Court vote before Election Day Trump expects to nominate woman to replace Ginsburg next week Video of Lindsey Graham arguing against nominating a Supreme Court justice in an election year goes viral MORE (R-Ky.) said: “Well it passed unanimously, apparently with the approval of President Obama and his DEA. You’ll have to ask the sponsors about it as to what the way forward will be.”

Several lawmakers are caught in the crossfire.

Rep. Tom Marino (R-Pa.) was the legislation’s chief advocate in the House, and on Tuesday withdrew his nomination to lead the Office of National Drug Control Policy.

Marino in a statement stood by his work on the bill, blamed the news media and a disgruntled DEA employee for the controversy and said he was stepping down to avoid being a distraction to Trump’s agenda.

“Given these facts and the importance of this legislation, [I] find it sad and disheartening that the news media have left behind any concept of balanced reporting and credited conspiracy theories from individuals seeking to avert blame from their own failures to address the opioid crisis that proliferated during their tenure,” he said.

Confirming Marino, an early backer of President Trump, would put moderate Republicans in states with high rates of deaths from opioids — such as Sens. Shelley Moore Capito Shelley Wellons Moore CapitoSecond GOP senator to quarantine after exposure to coronavirus GOP senator to quarantine after coronavirus exposure Hillicon Valley: Zuckerberg acknowledges failure to take down Kenosha military group despite warnings | Election officials push back against concerns over mail-in voting, drop boxes MORE (R-W.Va.) and Rob Portman Robert (Rob) Jones PortmanRomney undecided on authorizing subpoenas for GOP Obama-era probes Congress needs to prioritize government digital service delivery House passes B bill to boost Postal Service MORE (R-Ohio) — in a tough spot.

Capito said the law should be repealed and that she believes there’s momentum to do so.

Sen. Claire McCaskill Claire Conner McCaskillMomentum growing among Republicans for Supreme Court vote before Election Day Democratic-linked group runs ads in Kansas GOP Senate primary Trump mocked for low attendance at rally MORE (D-Mo.) introduced legislation to repeal the bill on Monday, and Senate Minority Whip Dick Durbin Richard (Dick) Joseph DurbinMcConnell focuses on confirming judicial nominees with COVID-19 talks stalled Senate Republicans signal openness to working with Biden Top GOP senator calls for Biden to release list of possible Supreme Court picks MORE (D-Ill.) also backs repeal.

But not all lawmakers are seeking to move that fast.

Sen. Orrin Hatch Orrin Grant HatchBottom line Bottom line Senate GOP divided over whether they'd fill Supreme Court vacancy MORE (R-Utah) was a sponsor of the original bill in the Senate. He’s referred to the report as flawed, and took to the Senate floor Monday to “set the record straight.”

Hatch said he negotiated the legislation with the DEA and that “DEA and [Department of Justice] themselves generated the language that critics now claim is so problematic.”

But, he told The Hill, he’s “open to try to resolve the problems.”

“I’m not against a bill that solves the problems in the right way,” he said.

Another sponsor, Sen. Sheldon Whitehouse Sheldon WhitehouseLWCF modernization: Restoring the promise Restaurant owner defends calamari as 'bipartisan' after Democratic convention appearance Warren calls on McConnell to bring Senate back to address Postal Service MORE (D-R.I.), is standing by the legislation, according to a spokesman.

“The DEA has provided Congress with no evidence that the law’s provisions have diminished the agency’s ability to crack down on bad actors,” the spokesman said, but added if a report on implementation raises concerns, the senator would revisit the issue.

The Judiciary Committee is now exploring holding an oversight hearing to examine if changes should be made and if the agency’s positions on the law have changed, Taylor Foy, a spokesman for the panel’s chairman, Sen. Chuck Grassley Charles (Chuck) Ernest GrassleySenate Republicans face tough decision on replacing Ginsburg What Senate Republicans have said about election-year Supreme Court vacancies Biden says Ginsburg successor should be picked by candidate who wins on Nov. 3 MORE (R-Iowa), wrote in an email.

He added that the DEA and Justice Department were both consulted on the bill at the time and both approved of it. The Washington Post-“60 Minutes” story suggested several DEA officials opposed the bill but their opinions were squashed by a confluence of factors.

Others say the law should at least be revisited.

“I’m a little surprised that it passed unanimously in both houses, was signed by President Obama and got no opposition from the DEA at the time,” Sen. Pat Toomey Patrick (Pat) Joseph ToomeyAppeals court rules NSA's bulk phone data collection illegal Dunford withdraws from consideration to chair coronavirus oversight panel GOP senators push for quick, partial reopening of economy MORE (R-Pa.) said. “That’s not the way controversial legislation usually ends up, but hey, if there’s problems, then we ought to revisit them.”

Portman was a leader in the effort to pass the Comprehensive Addiction and Recovery Act, a bright spot of bipartisanship last congressional session that authorized grants to battle the crisis.

He aired concerns with what the bill Marino sponsored appears to do.

“The DEA should be able to effectively go after bad actors and I think Congress should re-examine this issue,” Portman said in an emailed statement.

He touted his bill that would make it easier to stop mail shipments of powerful synthetic opioids.